Skip to main content
OpenTrials
Completed

NCT Number: NCT00285142

Effect of Rosiglitazone

To evaluate :

* acute effects of a single dose of 8 mg rosiglitazone (therapeutic dose) * on insulin secretion and * insulin sensitivity in 12 healthy male subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–35 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Centre d'Investigation Clinique

Montpellier, 34295, cedex 5, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • BMI between 18.0 and 24.0

Exclusion criteria

-

Treatment and study plan

rosiglitazone

Drug

Primary outcomes

  1. insulin response and insulin sensitivity assessed by 2-hours 10 mmol/l hyperglycemic clamp, started 45 min after treatment intake

Secondary outcomes

  1. insulin clearance

  2. basal glycemia and insulinemia

  3. tolerance

Sponsors and collaborators

Lead sponsor

University Hospital, Montpellier

Other

Registry information

Official study title

Assessment of the Effect of Rosiglitazone on Insulin Secretion in Healthy Volunteers

Important dates

Study start
2004
Study completion
2004
First posted
Feb 1, 2006
Registry last updated
Jun 10, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.